Navigation Links
Cheetah Medical's NICOM Non-Invasive Cardiac Output Monitor Featured in a Presentation at the Heart Failure Society of America (HFSA) Annual Meeting

Study Showed That NICOM can be Used to Accurately Measure Cardiac Output

During Cardiopulmonary Exercise Testing (CPX)

WASHINGTON, September 19 /PRNewswire/ -- Cheetah Medical Inc., developers of the Cheetah NICOM(TM) system, for non-invasive, real-time cardiac output monitoring, announced at HFSA the results of the study "Markers of ventilatory inefficiency in heart failure are related to peak exercise."

The study, led by Dr. Jon Myers of Stanford University and the VA Palo Alto Health Care System, used the NICOM to measure the cardiac output of 36 patients. Results showed that the NICOM accurately measured cardiac output. This is the first time that the NICOM was used in a study during cardiopulmonary exercise on heart failure patients.

Dr. Myers concluded, "NICOM provided accurate measurements of cardiac output and thoracic fluid during cardiopulmonary exercise. The possibility of using a non-invasive, accurate tool to measure cardiac output may provide clinicians with an important diagnostic tool that can contribute to optimization of CHF treatment and provide an early indication of disease escalation."

The NICOM(TM) Cardiac Output Monitor, developed by Cheetah Medical, is a portable system that utilizes the proprietary BIOREACTANCE(TM) technology to measure cardiac output in virtually any clinical setting. Cheetah considers BIOREACTANCE to be a superior modality to measure cardiac output, especially in clinical settings where continuous monitoring of cardiac output is imperative, and in clinical environments such as intensive care units, emergency departments and during stress tests, where there is significant electrical noise and patient movement.

Cheetah's BIOREACTANCE(TM) technology has been validated in the United States and Europe on hundreds of hemodynamically challenged patients in a variety of clinical settings, in the presence of significant environmental factors.

Laura Rector, General Manager of Cheetah Medical in the United States stated, "This study is important because, until the NICOM System, there has not been a technology as practical and simple, that is available to clinicians to accurately and easily provide exercise cardiac output. The NICOM System is a robust diagnostic tool for measuring cardiac output. The patented BIOREACTANCE technology opens opportunities for clinicians to improve patient care based on real-time accurate cardiac output measurements."

Ms. Rector continued, "We have now established our US Sales and Marketing Organization and we are excited about starting sales in the US Market. Based on the initial market reaction, there is clearly a great, untapped need for Cheetah's unique and proprietary technology."

About the BIOREACTANCE(TM) Technology

The Cheetah family of NICOM Cardiac Output Monitors implements the unique and proprietary BIOREACTANCE(TM) technology. BIOREACTANCE is a novel technology platform which analyzes changes in amplitude as well as frequency of electrical impulses as they traverse the chest. These changes are analyzed by software programming to provide a continuous, highly accurate and stable, non-invasive measurement of cardiac output and other cardiac parameters.

About the Company

Cheetah Medical is based in Tel Aviv, Israel and Indianapolis, Indiana. The company is establishing NICOM(TM) as a frontline tool to monitor cardiac function in inpatient and outpatient areas of high unmet need. Importantly, this unique and proprietary technology has been proven to provide accurate and reliable measurements of cardiac output, even during patient movement and across a variety of body types. These features enable the device to be used in several important clinical applications, including intensive care, anesthesia and peri-operative settings, step down, emergency room, dialysis clinic, cardiac care unit, ECO(TM) (Exercise CO testing), CRT-pacemaker optimization, thoracic fluid content (TFC) for acute and chronic heart failure management, home Holter monitoring of cardiac rhythm, thoracic fluid content and cardiac function together, and out-patient heart failure diagnosis/ monitoring.

For more information please visit or e-mail,

Contact: Laura Rector


SOURCE Cheetah Medical Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. GE Medicals Technologies Aid Battle Against Cancer
2. GE Medicals Acquisitions May Prompt More Purchases
3. DGGE Analysis for Non-Invasive Studies of Primate Diet
4. Radiology advance points way to non-invasive brain-cancer treatment
5. Criticare gets OK to market portable cardiac monitor
6. Versatile Reporter Vectors for Monitoring Viral Transduction
7. Cis-Reporting System Monitors Intracellular Calcium Mobilization
8. Cis-Reporting System Monitors Intracellular Calcium Mobilization
9. Monitoring transfection efficiency by green fluorescent protein (GFP) detection with the Agilent 2100 bioanalyzer
10. Monitoring Microbial Populations Using Real-Time qPCR on the MJ Research Opticon 2 System
11. Monitoring Bacterial Genetic Diversity in a Freshwater Lake Using TTGE and DNA Sequence Analysis
Post Your Comments:
(Date:11/24/2015)... , Nov. 24, 2015 Halozyme Therapeutics, Inc. (NASDAQ: ... in New York on Wednesday, December 2 ... Torley , president and CEO, will provide a corporate overview. ... York at 1:00 p.m. ET/10:00 a.m. PT . ... relations, will provide a corporate overview. --> th ...
(Date:11/24/2015)... /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS) (TSX: AEZ) (the ... the Toronto Stock Exchange, confirms that as of the ... developments that would cause the recent movements in the ... --> About Aeterna Zentaris Inc. ... Aeterna Zentaris is a specialty biopharmaceutical company engaged in ...
(Date:11/24/2015)... ... 24, 2015 , ... The Academy of Model Aeronautics (AMA), led by its ... as Multirotor Grand Prix, to represent the First–Person View (FPV) racing community. , FPV ... embraced this type of racing and several new model aviation pilots have joined the ...
(Date:11/24/2015)... CITY , Nov. 24, 2015 /PRNewswire/ - ... "Company") announced today that the remaining 11,000 post-share ... Share Purchase Warrants (the "Series B Warrants") subject ... were exercised on November 23, 2015, which will ... Shares.  After giving effect to the issuance of ...
Breaking Biology Technology:
(Date:11/11/2015)... MedNet Solutions , an innovative SaaS-based eClinical technology company that ... announce that it will be a Sponsor of the ... held November 17-19 in Hamburg , Germany.  ... iMedNet , MedNet,s easy-to-use, proven and affordable eClinical ... able to deliver time and cost savings of up to ...
(Date:11/9/2015)... ) ... "Global Law Enforcement Biometrics Market 2015-2019" ... ) has announced the addition of ... 2015-2019" report to their offering. ... ) has announced the addition of the ...
(Date:11/2/2015)... PARK, Calif. , Nov. 2, 2015  SRI ... $9 million to provide preclinical development services to the ... the contract, SRI will provide scientific expertise, modern testing ... wide variety of preclinical pharmacology and toxicology studies to ... --> The PREVENT Cancer Drug Development ...
Breaking Biology News(10 mins):